IntroductIon
Virus-derived vectors have become one of the most promising gene delivery systems for human cells. Especially lentiviral vectors (LVs) provide an outstanding therapeutic potential by stable longterm transgene expression in nondividing cells. 1, 2 The particle surface design of γ-retroviral vectors and LVs has been constantly improved during the last 20 years, starting with the use of murine leukemia virus envelope proteins, those of other γ-retroviruses and finally the glycoprotein (G) of the vesicular stomatitis virus (VSV), which mediates efficient transduction of basically all human cell types. 3 More recent developments aim at restricting the vector tropism at the level of cell entry to the target cell population defined by a specific surface antigen. It is expected that this will facilitate in vivo gene transfer strategies and reduce the vector dose required for successful therapy. Promising progress in this direction has recently been obtained by engineering viral envelope proteins that have the receptor attachment and membrane fusion functions separated into two glycoproteins. [4] [5] [6] [7] The measles virus (MV) glycoproteins, namely, hemagglutinin (H) and fusion protein (F), mediate cell entry directly at the cell membrane in a pH-independent manner. 8 The H-protein attaches the virus to the natural MV receptors CD46 and signaling lymphocyte-activation molecule and forms a complex with F protein to accomplish its fusion helper function. We have recently demonstrated that F and H can be incorporated into LVs, provided their N-terminal cytoplasmic tails are truncated.
9 Such MV-LVs were then retargeted to various cell types using a mutant of the H-protein with 4 point mutations that lost use of its natural receptors and fusing a cell type-specific single-chain antibody (scFv) to the C-terminus of the H-protein extracellular domain. 9, 10 The aim of this study was to evaluate designed ankyrin repeat proteins (DARPins) as an alternative targeting domain to scFvs for MV-LVs. DARPins are based on naturally occurring ankyrin repeat proteins-a ubiquitously expressed protein family that mediates specific protein-protein interactions. 11 By a consensusdesign approach an ankyrin repeat module comprising 33 amino acid residues was derived in which residues that potentially can interact with the target are randomized. By combining 2-3 of these repeats and flanking them by N-and C-capping repeats (termed N2C or N3C), combinatorial libraries of DARPins have been obtained. These libraries can be selected against almost any kind of ligand using ribosome display (library diversities >10 12 ) or phage display (library diversity >10 10 ). 12, 13 Specific binders with affinities in the pmol/l range have been obtained at high frequency. These molecules have no cysteines, and show very low tendencies of aggregation. They may thus have great promise in their application as fusion proteins to membrane proteins as the ones investigated here, where other fused targeting proteins, such as some aggregation-prone scFv fragments, would compromise the efficiency of correct assembly and thereby lead to low display levels.
Here, we report that DARPins can be used to re-target LVs to HER2/neu positive cancer cells. Belonging to the epidermal growth factor family HER2/neu is a type-I receptor tyrosine kinase, which is highly expressed on breast, ovarian, colon and pancreatic cancer cells but shows low level or no expression on all normal human tissue.
14 By using a panel of six DARPins exhibiting distinct affinities for HER2/neu and using different binding sites, we could show that chimeric H-DARPin proteins are well expressed and incorporated in LVs and able to redirect membrane fusion via HER2/neu. The data suggest that a membrane distal binding site for HER2/neu mediates optimal cell entry of DARPin displaying LVs. By systemic application in a bilateral xenograft mouse model we demonstrate the in vivo targeting potential of these alternative binding molecules.
results

H-dArPin surface expression levels
Starting from plasmid pCG-H-α-CD20 encoding an H-protein mutated in its receptor binding sites and fused to a CD20-specific scFv, 9 we substituted the scFv coding sequence for that of six HER2/neu-specific DARPins 15, 16 resulting in constructs pH-D9.29, pH-D9.26, pH-D9.16, pH-D9.01, pH-DH14R, and pH-DG3 (Figure 1a) . As controls, we also generated an expression plasmid for an H-protein displaying the HER2/neu-specific scFv 4D5 (pH-scFv4D5) 17 and scFv 7A5, which does not allow cell surface expression as H fusion protein. 18 As sufficient surface expression of H fusion proteins is a critical prerequisite for the efficient pseudotyping of LVs, we transfected cells with the H-DARPin expression plasmids and determined the cell surface expression levels by fluorescence-activated cell sorter analysis. All six H-DARPin proteins showed high surface expression rates in a similar range (mean fluorescence intensity 1,500-3,200) (Figure 1b) . H-DARPin-9.29 exhibited the highest surface expression (mean fluorescence intensity = 3,200), which was about twice that of the H-scFvCD20 protein (mean fluorescence intensity = 1,600) and almost three times higher than that of H-scFv4D5 (MFI = 1,100).
H-dArPin fusion helper function
Besides high surface expression levels of the H-DARPin proteins, it is essential that their fusion helper function is maintained for successful retargeting of LVs. To assess the fusion helper function of the H-DARPin proteins, the corresponding expression plasmids were co-transfected with pCG-F∆30 (encoding a C-terminally truncated F protein, 9 Figure 1a ) into SK-OV-3 cells, which express high levels of HER2/neu ( Table 1) . Membrane fusion can then be followed by the formation of syncytia through fusion of adjacent cells. All tested H-DARPin proteins caused syncytia formation. Quantification revealed that the H-DH14R and the H-DG3 proteins exhibited the strongest fusion helper function reaching almost 70% of that of the unmodified H-protein (Figure 2a) .
To investigate the influence of the HER2/neu receptor density on cell-cell fusion, we generated a panel of stably transfected CHO clones expressing different HER2/neu surface levels ( Table 1 (SwissProt P08362) . 31 Four point mutations in the ectodomain (ED) ablating binding to CD46 and signaling lymphocyte-activation molecule (the natural receptors) are indicated. 9 An N-terminal cytoplasmic tail truncation by 18 amino acids (CT∆18) allows stable incorporation into lentiviral particles. 9 The C-terminus of H is fused via a SfiI site to the DARPin, resulting in the sequence EDGTNAAQPADLGKKL where the first underlined sequence is the C-terminus of H and the second is the N-cap of the DARPin. The DARPin terminates in the sequence EILQKLNAAARGSHHHHHH (DARPin C-cap is underlined). The transmembrane domain (TM) and the His-tag are indicated. (b) Expression plasmids for six different H-DARPin and three H-scFv fusion proteins were transfected into HEK-293T cells. Surface expression was analyzed after 48 hours using a His-tag-specific antibody (PE-labeled). H-scFvCD20 and H-scFv7A5 were used as positive and negative controls. Likewise, HER2/neu negative cells did not form syncytia, demonstrating the HER2/neu specificity of the process. Plotting the membrane fusion activities of the proteins against the receptor densities demonstrated a direct correlation between both parameters (Figure 2c) . Independent from the receptor levels, the fusion helper function of H-DG3 and H-H14R proteins was about fourfold more efficient than the function of the H-scFv4D5 protein (Figure 2c ).
Generation and characterization of Her2/neu-targeted lVs
Having demonstrated HER2/neu-specific membrane fusion helper function, the H-DARPin proteins were next used for pseudotyping LVs. The corresponding vector particles (D9.29-LV, D9.26-LV, D9.16-LV, D9.01-LV, DH14R-LV, DG3-LV) were first assayed for the incorporation levels of the H-DARPin proteins. All six H-DARPin proteins were detectable in the particles albeit at different levels. There were only very low levels of the proteins H-D9.01 and H-scFv4D5 incorporated, while H-D9. 16 showed moderate incorporation levels ( Figure 3, Table 2 ). High incorporation levels were observed for the proteins H-DG3, H-D9.26 and H-DH14R, and the strongest incorporation for H-DARPin-9.29 ( Figure 3, Table 2 ).
Next, we determined the targeting potential of the DARPin-LV particles by transducing a set of cell lines expressing different HER2/neu levels, i.e., HER2/neu negative CHO-K1, low level HER2/neu expressing HEK-293T and high level HER2/neu expressing CHO-Her2-k6 and SK-OV-3 cells (see Table 1 and CHO-Her2-k6 cells, all vectors reached at least tenfold higher titers. Moreover, most DARPin displaying LVs were considerably more efficient in mediating gene transfer via HER2/neu than 4D5-LV, which was 10-30 times less efficient. D9.29-LV was especially effective on SK-OV-3 cells where it showed the highest titers of all vector types tested (Figure 4b) .
transduction of mixed cell populations and in vivo application of Her2/neu-targeted lVs
After demonstration of HER2/neu receptor specificity and identification of the most effective H-DARPin protein (i.e., H-DARPin-9.29), we assessed the target cell specificity in co-cultures of CHO-Her2-k6 and CHO-K1 cells. VSV-Gpseudotyped LV (VSV-G-LV) transduced both cell lines at equal efficiency ( Figure 5 ). In contrast, D9.29-LV only transduced CHO-Her2-k6 cells, even when these were clearly underrepresented ( Figure 5) . The in vivo targeting potential of D9.29-LV was assessed in a xenograft mouse model carrying a HER2/neu-positive (SK-OV-3 cells) and a HER2/neu-negative tumor (U87MG cells). After both tumors were fully vascularized the luciferase transferring vectors D9.29-LV luc and VSV-G-LV luc were injected systemically through the tail vein and mice were analyzed using charged-coupled device imaging. D9.29-LV luc showed strong luciferase activity in the SK-OV-3 tumor already 3 days after injection while luciferase activity was below the level of detection in the U87MG tumor or elsewhere in the mouse body (data not shown). Also after 2 weeks, luciferase activity could only be detected in the SK-OV-3 tumor, but not in the U87MG tumor or in spleen and liver (Figure 6a) . In contrast VSV-G-LV luc injected mice showed the most prominent signals in spleen and liver, whereas both tumors emitted a comparably low signal indistinguishable from other tissues (Figure 6a) . Because the intensity of the charged-coupled device imaging can be influenced by variables such as depth of tissue and positioning of the animal during imaging, mice were killed and luciferase activitiy in organ lysates was quantified. D9.29-LV luc injected mice showed the strongest luciferase activity in SK-OV-3 tumor lysates (4.0 × 10 2 RLU/ µg protein), whereas the activity in U87MG tumor lysates was >1000-fold lower and remained at background level (3.0 × 10 −1 RLU/µg protein) (Figure 6b) . Besides the target tumor, a significant activity just above background was only detected in spleen (0.7 × 10 1 RLU/µg protein). In contrast, VSV-G-LV luc injected mice revealed by far the most prominent signal in spleen (8.5 × 10 4 RLU/µg protein) and liver (5.1 × 10 3 RLU/µg protein), but comparably low luciferase activity in both tumor lysates (2.5 × 10 2 RLU/µg protein for SKOV and 9.3 × 10 2 RLU/µg protein for U87MG) (Figure 6b ).
dIscussIon
Here, we present proof of principle for applying DARPins as targeting domain of LV vectors. While adenovirus has recently been retargeted with DARPins 19 to our knowledge, this is the first description and in vivo demonstration of this type of application for DARPins for lentiviral gene transfer vector. Six different HER2/neu-specific DARPins, previously selected from DARPin libraries by ribosome or phage display, 15, 16 were fused to the H-protein ectodomain at its C-terminus. A critical parameter for efficient LV particle incorporation of H proteins fused to targeting domains is their efficient cell surface expression. It was remarkable that all six H-DARPin proteins tested were readily expressed at the surface of HEK-293T cells. We did not observe any difference in surface expression between DARPins consisting of two or of three ankyrin repeats between the capping repeats. In each case, the surface expression levels were higher than those of H proteins fused to an scFv fragment, the HER2/neu-specific 4D5 or the CD20-specific scFv, 20 previously used to establish this targeting system. 9 Accordingly, all the H-DARPin fusion proteins were detected in vector particles, most of them at higher levels than H-scFv proteins. Moreover, while six out of six tested H-DARPin proteins were expressed at the cell surface and incorporated into vector particles, this was the case for only 12 of in total 25 H-scFv proteins tested so far (Schneider and Buchholz, unpublished results). When directly compared to a specific-scFv (4D5), 17 which recognized the same domain (IV) of HER/neu with a similar high affinity as DARPins G3 and H14R, between ten and 30-fold higher gene transfer efficiencies were observed for the DARPin displaying vectors ( Table 2) . Thus, DARPins seem to be better suited as targeting domain in context of the MV H-protein than scFv fragments. Even though in the current comparison only one scFv fragment was included, 4D5 scFv is known to be stable and well expressed, 21 and thus one with already above-average biophysical properties. DARPins have no disulfide bonds and are very resistant to aggregation, and thus probably more compatible with the folding and assembly of integral membrane proteins.
Most retrovirus receptors are multiple transmembrane spanning integral membrane proteins with rather small extracellular domains thus mediating binding in close proximity to the cell membrane. 22 For MV, it was shown that the distance between the viral binding site and the cell membrane correlates reciprocally with membrane fusion efficiency. 23 However, in such a receptor protein, the virus binding site is well accessible. If a membrane protein with a large, multi-domain extracellular region is used as receptor for the virus, it is essential that the epitope is accessible for the targeting domain within the context of the viral surface protein, in this case the MV H-protein. Unlike other members of the epidermal growth factor -receptor family, HER2/neu dimerises in absence of ligand contact. 24 This results in an exposed dimerisation domain, but covers partially the membrane proximal domain IV, 25 which therefore may be difficult to access by LVs binding to this domain. This may explain why DARPins binding to the membrane distal domains I-III of HER2/neu mediated more efficient gene transfer than those binding to the membrane proximal domain IV. It appears that affinity plays a smaller role, as gene transfer efficiency did not correlate with affinity ( Table 2) . One explanation for this finding would be multivalent binding, which would increase the functional affinity of the viral particle.
To assess the influence of the HER2/neu density on membrane fusion and gene transfer efficiency we analyzed a panel of cell lines expressing HER2/neu in a range of three orders of magnitude. We found that HER2/neu densities below 1,000 molecules per cell were insufficient to allow efficient membrane fusion and particle entry. With increasing densities, both syncytia formation and particle entry increased. Optimal gene transfer efficiency was observed above a density of 10 5 molecules per cell. Such an expression level of HER2/neu is found in certain types of cancer cells, such as e.g., the ovarian cancer cell line SK-OV-3. Thus, targeting specificity of these vectors critically depends on receptor density, which will facilitate the discrimination between cancer cells and noncancer cells.
Recently, a panel of recombinant MVs displaying HER2/neuspecific scFvs that ranged in their affinities from 10 −6 to 10 −11 mol/l have been described. 26 An affinity threshold of 1.6 × 10 −8 mol/l for the displayed scFv was identified at which cell-cell fusion and cell entry of the virus proceeded efficiently. The affinities of the DARPins we used ranged from 7 × 10 −8 mol/l to 10 −10 mol/l, and thus were all above this threshold level. Our data are thus in line with those of Hasegawa et al. and extend them by demonstrating that, at least for MV-LV vector particles, above the threshold level, the location of the targeting domain binding site on HER2/neu is more important than affinity.
A surprising outcome of our study is the high tumor target specificity of D9.29-LV when applied by tail vein injection. It is well established that VSV-G-LV mainly accumulates in spleen and liver. 6, 27 Our results are well in line with this revealing at least 100-fold more luciferase activity in spleen than in tumor tissue for VSV-G-LV. Previous attempts to detarget LVs from spleen and liver by surface engineering had limited success. Morizono et al. targeted lung tumor cells applying LVs pseudotyped with Sindbis virus envelope proteins bound to a tumor cell surface antigen-specific monoclonal antibody. They achieved a threefold higher luciferase activity in target compared to nontarget tissue. 5 D9.29-LV in contrast results in at least 40-fold more luciferase activity in the target tumor than in off-target tissue. It is important to mention that off-target tissue was not only of murine origin, which is devoid of MV receptors, but also included a human cell-based tumor expressing the MV receptor CD46 at high density. Thus, targeted MV-LV vectors are not only highly specific in vitro 9, 10 or after local in vivo application 10 but also when applied systemically. The possibility to apply DARPins for LV targeting further broadens the applicability of MV-LV vectors. DARPins can be generated with specificity for essentially any surface molecule, and many such DARPins are already available. 16, 28 
